Clinical Trial Update: Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older [Phase 1]

View source ↗

Summary

A Phase 1 trial of intravenous Erwinia chrysanthemi asparaginase in newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia patients aged …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Erwinia chrysanthemi asparaginase (Erwinia chrysanthemi asparaginase)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Acute Lymphoblastic Leukemia (ALL), Newly Diagnosed Philadelphia Chromosome Negative | Phase 1 | Status: WITHDRAWN